Syndrome
What is metabolic syndrome?
Metabolic syndrome is the name for a group of risk factors for heart disease, diabetes, and other health problems. You can have just one risk factor, but people often have several of them together. When you have at least three of them, it is called metabolic syndrome. These risk factors include:
- A large waistline, also called abdominal obesity or "having an apple shape." Too much fat around the stomach is a greater risk factor for heart disease than too much fat in other parts of the body.
- Having a high triglyceride level. Triglycerides are a type of fat found in the blood.
- Having a low HDL cholesterol level. HDL is sometimes called the "good" cholesterol because it helps remove cholesterol from your arteries.
- Having high blood pressure. If your blood pressure stays high over time, it can damage your heart and lead to other health problems.
- Having a high fasting blood sugar. Mildly high blood sugar may be an early sign of diabetes.
The more factors you have, the higher your risk for heart disease, diabetes, and stroke is.
What causes metabolic syndrome?Metabolic syndrome has several causes that act together:
- Overweight and obesity
- An inactive lifestyle
- Insulin resistance, a condition in which the body can't use insulin properly. Insulin is a hormone that helps move blood sugar into your cells to give them energy. Insulin resistance can lead to high blood sugar levels.
- Age - your risk goes up as get older
- Genetics - ethnicity and family history
People who have metabolic syndrome often also have excessive blood clotting and inflammation throughout the body. Researchers don't know whether these conditions cause metabolic syndrome or worsen it.
Who is at risk for metabolic syndrome?The most important risk factors for metabolic syndrome are:
- Abdominal obesity (a large waistline)
- An inactive lifestyle
- Insulin resistance
There are certain groups of people who have an increased risk of metabolic syndrome:
- Some racial and ethnic groups. Mexican Americans have the highest rate of metabolic syndrome, followed by whites and blacks.
- People who have diabetes
- People who have a sibling or parent who has diabetes
- Women with polycystic ovary syndrome (PCOS)
- People who take medicines that cause weight gain or changes in blood pressure, blood cholesterol, and blood sugar levels
Most of the metabolic risk factors have no obvious signs or symptoms, except for a large waistline.
How is metabolic syndrome diagnosed?Your health care provider will diagnose metabolic syndrome based on the results of a physical exam and blood tests. You must have at least three of the risk factors to be diagnosed with metabolic syndrome:
- A large waistline, which means a waist measurement of
- 35 inches or more for women
- 40 inches or more for men
- A high triglyceride level, which is 150 mg/dL or higher
- A low HDL cholesterol level, which is
- Less than 50 mg/dL for women
- Less than 40 mg/dL for men
- High blood pressure, which is a reading of 130/85 mmHg or higher.
- A high fasting blood sugar, which is 100 mg/dL or higher
The most important treatment for metabolic syndrome is a heart-healthy lifestyle, which includes:
- A heart-healthy eating plan, which limits the amount of saturated and trans fats that you eat. It encourages you to choose a variety of nutritious foods, including fruits, vegetables, whole grains, and lean meats.
- Aiming for a healthy weight
- Managing stress
- Getting regular physical activity
- Quitting smoking (or not starting if you don't already smoke)
If making lifestyle changes is not enough, you may need to take medicines. For example, you may need medicines to lower cholesterol or blood pressure.
Can metabolic syndrome be prevented?The best way to prevent metabolic syndrome is through the heart-healthy lifestyle changes.
NIH: National Heart, Lung, and Blood Institute
Syndrome FDA Approved Drugs
- A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in patients with non-st elevation acs.
- Method for relieving constipation in a human patient that comprises administering to the patient a dosage unit comprising (i) 24mcg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
- Method for relieving constipation in a patient with opioid-induced constipation that comprises administering to the patient a dosage unit comprising(i)24microg+/- 10% of a drug substance and (ii) a pharmaceutically suitable excipient.
- Method for relieving or treating constipation in a human constipated patient.
- Method for relieving or treating constipation in a patient with irritable bowel syndrome.
- Method for relieving or treating constipation in a patient with opioid-induced constipation.
- Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome.
- Method for the long term treatment of chronic constipation in a human subject.
- Method for treating constipation by opening cic channels in a mammalian subject.
- Method for treating constipation in a patient with opioid-induced constipation by opening cic channels.
- Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome.
- Method for treating opioid-induced constipation.
- Method of relieving or preventing constipation in a human constipated patient.
- Method of relieving or preventing constipation in a human patient with opioid-induced constipation.
- Method of treating constipation in a patient with irritable bowel syndrome by opening chloride channels (cic).
- Method of treating constipation in a patient with irritable bowel syndrome.
- Use in relieving or preventing constipation in a human patient with a dosage unit comprising 24microg+/- 10% of a drug substance and a pharmaceutically suitable excipient.
- Use in relieving or preventing constipation in a patient with opioid-induced constipation with a dosage unit comprising 24microg +/- 10% of a drug substance and a pharmaceutically suitable excipient.
- Method of inhibiting platelet aggregation.
- Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
- Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
- Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
- Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
- Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
- Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
- Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
- Treatment of myocardial infarction.
- Treatment of post-myocardial infarction.
- Treatment of stable and unstable angina.
- Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
- Treatment of stroke.
- Treatment of thrombotic stroke.
- Treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
- Management of postherpetic neuralgia (phn) in adults.
- Treatment of moderate-to-severe primary restless leg syndrome in adults.
Eli Lilly And CoMay 26, 2015
- Treating cushing's syndrome.
- Method of treating chronic idiopathic constipation in adult patients..
- Method of treating irritable bowel syndrome with constipation in adult patients..
- Method of treating irritable bowel syndrome with constipation in adults.
- Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids).
- Treatment of moderate to severe primary restless legs syndrome (rls).
- A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
- Treatment of restless legs syndrome by application of claimed transdermal delivery system.
- Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system.
- A process for treating a patient suffering from parkinson's syndrome and in need of treatment.
- Treatment of male patient having a disease or condition responsive to a teratogenic drug.
- Use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl).
- Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds).
- Use of revlimid (lenalidomide) for the treatment of multiple myeloma.
- Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).
- Use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha.
- Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide).
- Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).
- Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)..
- The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.
- Method of treating travelers' diarrhea.
- The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence.
Home Remedies for Syndrome
   Eat more nuts, such as almonds, as your period approaches.
Mechanism - Riboflavins boosts neurotransmitters that reduce PMS symptomsFedup | November 5th, 2017
   Citriodiol® consists mainly of p-menthane-3,8-diol or PMD and has anti-viral activity against the coronavirus SARS-CoV-2. It has other names, after its ingredient:
Oil of lemon Eucalyptus (OLE) – USA (EPA & CDC)
Oil of lemon eucalyptus, hydrated, cyclized – Canada (PMRA)
Oil of Lemon Eucalyptus (hydrated, cyclized) – Australia (APVMA)
Eucalyptus citriodora oil, hydrated, cyclized (abbreviated for informal use as EC Oil (H/C)) - European Union
Leaves and branches are har...
Mechanism - PMD (p-menthane-3,8-diol)JackR | August 26th, 2020